Moneycontrol PRO
glenmark pharma
Jump to
  • Glenmark Consolidated June 2022 Net Sales at Rs 2,777.29 crore, down 6.33% Y-o-Y Aug 12, 2022 10:22 AM IST

    Glenmark Consolidated June 2022 Net Sales at Rs 2,777.29 crore, down 6.33% Y-o-Y

  • Glenmark Standalone June 2022 Net Sales at Rs 1,911.93 crore, down 10.75% Y-o-Y Aug 11, 2022 11:55 AM IST

    Glenmark Standalone June 2022 Net Sales at Rs 1,911.93 crore, down 10.75% Y-o-Y

  • Glenmark Pharma arm gets final USFDA nod for birth control capsules Jul 29, 2022 10:53 AM IST

    Glenmark Pharma arm gets final USFDA nod for birth control capsules

    The approval granted by the US Food & Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc is for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules of strength 1 mg/20 mcg, the company said in a statement.

  • Glenmark launches fixed-dose combination drug for asthma in India Jun 16, 2022 12:22 PM IST

    Glenmark launches fixed-dose combination drug for asthma in India

    The company said the drug will be available in three strengths with a fixed dose of Indacaterol and variable doses of Mometasone to be taken once daily.

  • Glenmark Pharma shares hit 52-week low on reports of USFDA inspection at Baddi plant Jun 13, 2022 01:32 PM IST

    Glenmark Pharma shares hit 52-week low on reports of USFDA inspection at Baddi plant

    Company's consolidated profit after tax declined 26 percent to Rs 173 crore for the fourth quarter ended March 31, 2022.

  • Glenmark Consolidated March 2022 Net Sales at Rs 3,019.15 crore, up 5.57% Y-o-Y May 31, 2022 10:48 AM IST

    Glenmark Consolidated March 2022 Net Sales at Rs 3,019.15 crore, up 5.57% Y-o-Y

  • Glenmark Q4 net dips 26% at Rs 173 crore May 28, 2022 10:41 AM IST

    Glenmark Q4 net dips 26% at Rs 173 crore

    Consolidated revenues of the drug firm rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the year-ago period, recording an increase of 6 per cent year-on-year

  • Bet on these two stocks for decent returns in short term, although market lacks momentum Apr 14, 2022 10:42 AM IST

    Bet on these two stocks for decent returns in short term, although market lacks momentum

    From the second week of October 21, momentum oscillator RSI (relative strength index - 14) is reading in a 'lower low lower high' formation on the weekly timeframe which indicates a lack of momentum in the current trend.

  • Glenmark Pharma rises 2% as Lacosamide tablets get final approval from US watchdog Mar 21, 2022 09:52 AM IST

    Glenmark Pharma rises 2% as Lacosamide tablets get final approval from US watchdog

    The company plans to launch the product immediately.

  • Glenmark Pharma share price rises 2% on launch of nasal spray for COVID-19 patients Feb 09, 2022 10:07 AM IST

    Glenmark Pharma share price rises 2% on launch of nasal spray for COVID-19 patients

    The nitric oxide nasal spray, to be sold under the brand name FabiSpray, is for treating adult patients with COVID-19 who have a high risk of progression of the disease, the company has said

  • Glenmark Pharma arm gets final USFDA approval for blood pressure drug Jan 27, 2022 10:47 AM IST

    Glenmark Pharma arm gets final USFDA approval for blood pressure drug

    The approval granted to Glenmark Pharmaceuticals Inc, USA by the United States Food & Drug Administration (USFDA) is for Bisoprolol Fumarate and Hydrochlorothiazide tablets of strengths 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 MG, the company said in a statement.

  • Glenmark Pharma inks exclusive licensing agreement with Lotus International Jan 20, 2022 10:46 AM IST

    Glenmark Pharma inks exclusive licensing agreement with Lotus International

    Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for manufacturing and supply of Ryaltris.

  • Glenmark Pharma gets tentative USFDA nod for generic Regadenoson injection Jan 17, 2022 10:26 AM IST

    Glenmark Pharma gets tentative USFDA nod for generic Regadenoson injection

    Regadenoson injection is given during the preparation for a radiologic examination of blood flow through the heart to test for coronary artery disease.

  • Trade Spotlight | What should you do with Glenmark Pharma, Navin Fluorine, Raymond & Birlasoft stocks? Nov 24, 2021 07:09 AM IST

    Trade Spotlight | What should you do with Glenmark Pharma, Navin Fluorine, Raymond & Birlasoft stocks?

    Here's what Mazhar Mohammad of chartviewindia.in, recommends investors should do with these stocks when the market resumes trading today.

  • Neutral Glenmark Pharma; target of Rs 560: Motilal Oswal Nov 16, 2021 03:24 PM IST

    Neutral Glenmark Pharma; target of Rs 560: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 560 in its research report dated November 15, 2021.

  • Glenmark Consolidated June 2021 Net Sales at Rs 2,964.90 crore, up 26.45% Y-o-Y Aug 25, 2021 10:44 AM IST

    Glenmark Consolidated June 2021 Net Sales at Rs 2,964.90 crore, up 26.45% Y-o-Y

  • Glenmark Standalone June 2021 Net Sales at Rs 2,142.12 crore, up 27.29% Y-o-Y Aug 24, 2021 09:11 AM IST

    Glenmark Standalone June 2021 Net Sales at Rs 2,142.12 crore, up 27.29% Y-o-Y

  • Neutral Glenmark Pharma; target of Rs 600: Motilal Oswal Aug 19, 2021 02:11 PM IST

    Neutral Glenmark Pharma; target of Rs 600: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 600 in its research report dated August 16, 2021.

  • Glenmark Standalone June 2021 Net Sales at Rs 2,142.12 crore, up 27.29% Y-o-Y Aug 17, 2021 03:11 PM IST

    Glenmark Standalone June 2021 Net Sales at Rs 2,142.12 crore, up 27.29% Y-o-Y

  • Glenmark Life Sciences IPO subscribed 2.78 times on day 1, retail portion booked 5.16 times Jul 27, 2021 11:27 AM IST

    Glenmark Life Sciences IPO subscribed 2.78 times on day 1, retail portion booked 5.16 times

    The subsidiary of Glenmark Pharma plans to raise Rs 1,513.6 crore through the public issue which comprises a fresh issue of Rs 1,060 crore, and an offer for sale of 63 lakh equity shares by promoter.

  • Is Glenmark Life Sciences another Divi's in the making? Jul 22, 2021 09:49 AM IST

    Is Glenmark Life Sciences another Divi's in the making?

    Glenmark Life Sciences' IPO timing is opportune, but it needs to strike deep relationships with global innovators and attain market leadership in key products

  • Glenmark Pharma Q1 PAT seen up 23.3% YoY to Rs 313.1 cr: KRChoksey Jul 13, 2021 11:55 AM IST

    Glenmark Pharma Q1 PAT seen up 23.3% YoY to Rs 313.1 cr: KRChoksey

    Net Sales are expected to increase by 23.1 percent Y-o-Y (up 1 percent Q-o-Q) to Rs 2,887 crore, according to KRChoksey.

  • Glenmark Pharma gets USFDA nod for inhalation product Jun 23, 2021 11:31 AM IST

    Glenmark Pharma gets USFDA nod for inhalation product

    The approved product is a generic version of Brovana Inhalation Solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc.

  • Glenmark Pharma’s API Arm Glenmark Life Sciences may launch IPO in July to raise up to Rs 1,700 crore Jun 18, 2021 03:17 PM IST

    Glenmark Pharma’s API Arm Glenmark Life Sciences may launch IPO in July to raise up to Rs 1,700 crore

    The management has indicated that the API growth outlook remains strong for the next two-three years owing to a favourable demand-supply scenario.

  • Neutral Glenmark Pharma; target of Rs 580: Motilal Oswal Jun 01, 2021 12:59 PM IST

    Neutral Glenmark Pharma; target of Rs 580: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 580 in its research report dated May 31, 2021.

Sections
ISO 27001 - BSI Assurance Mark